UPDATE 1-Biogen profit smashes estimates on Spinraza demand

July 25 (Reuters) – Biogen Inc’s second-quarterprofit blew past estimates, driven by higher-than-expecteddemand for its recently approved spinal muscular atrophy (SMA)drug, Spinraza.
The post UPDATE 1-Biogen profit smashes estimates on Spinraza demand appeared first on RocketNews | Top News Stories From Around the Globe.